| 35.17 0.24 (0.69%) | 09-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 44.53 | 1-year : | 52.01 |
| Resists | First : | 38.13 | Second : | 44.53 |
| Pivot price | 35.87  |
|||
| Supports | First : | 34.03 | Second : | 31.51 |
| MAs | MA(5) : | 35.4 |
MA(20) : | 35.65  |
| MA(100) : | 32.45 |
MA(250) : | 28.17 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.5 |
| %K %D | K(14,3) : | 34.8 |
D(3) : | 41.4 |
| RSI | RSI(14): 49.5 |
|||
| 52-week | High : | 38.13 | Low : | 20.64 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ PHVS ] has closed above bottom band by 32.2%. Bollinger Bands are 3.5% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 35.86 - 36 | 36 - 36.16 |
| Low: | 33.79 - 33.94 | 33.94 - 34.1 |
| Close: | 34.9 - 35.13 | 35.13 - 35.4 |
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
Wed, 02 Sep 2026
Understanding Momentum Shifts in (PHVS) - Stock Traders Daily
Sun, 30 Aug 2026
Pharvaris (PHVS) Pulls Back 4.5% to $35.32 as Shares Approach Key Support - Fibonacci Time Zone - vinanet.vn
Tue, 18 Aug 2026
Pharvaris (PHVS) CEO sells 2,292 shares after RSU vesting - Stock Titan
Thu, 13 Aug 2026
Citizens raises Pharvaris stock price target to $75 on trial progress - Investing.com
Wed, 12 Aug 2026
Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date - Stock Titan
Fri, 31 Jul 2026
Wall Street Analysts Think Pharvaris (PHVS) Could Surge 43.03%: Read This Before Placing a Bet - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 70 (M) |
| Shares Float | 44 (M) |
| Held by Insiders | 6 (%) |
| Held by Institutions | 92.8 (%) |
| Shares Short | 1,190 (K) |
| Shares Short P.Month | 986 (K) |
| EPS | -3.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.4 % |
| Return on Equity (ttm) | -70.5 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -155 (M) |
| Levered Free Cash Flow | -90 (M) |
| PE Ratio | -11.61 |
| PEG Ratio | 0 |
| Price to Book value | 7.03 |
| Price to Sales | 0 |
| Price to Cash Flow | -15.91 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|